

AROA BIOSURGERY FY26 PRELIMINARY RESULT HIGHLIGHTS (UNAUDITED)

Aroa Biosurgery Limited (ASX: ARX) is pleased to announce preliminary unaudited result highlights for the year ended 31 March 2026.

FY26 PRELIMINARY RESULT HIGHLIGHTS

- **Total revenue of NZ\$104 million** (actual), NZ\$101 million (constant currency¹), **exceeding FY26 guidance** of NZ\$92-100 million (constant currency)
- **Normalised EBITDA² of NZ\$11-12 million** (actual), NZ\$10-\$11 million (constant currency), **exceeding FY26 guidance** of NZ\$ 5-8 million (constant currency)
- **Positive net cash flow of NZ\$5 million**
- **Cash balance of NZ\$27 million at 31 March 2026**, up from NZ\$23 million at 30 Sept 2025

The Company expects total revenue of approximately NZ\$104 million on an actual basis (NZ\$101 million constant currency), representing growth of 21% (constant currency) on FY25 results. This performance reflects stronger than anticipated sales in the Myriad™ portfolio, with growth of 52% (constant currency) on FY25 sales.

Normalised EBITDA is likely to be in the range of NZ\$11 -12 million on an actual basis (NZ\$10-\$11 million constant currency), which primarily reflects the increased level of revenue. Changes in the timing of project related costs (notably in relation to Enivo and TelaBio development projects) also had some impact. These costs are now expected to fall in FY27.

On an actual basis, the revenue and normalised EBITDA results also benefitted from favourable foreign exchange movements during the period.

The unaudited results exceed the Company's FY26 revenue guidance of NZ\$92-100 million and normalised EBITDA guidance of NZ\$5-8 million (constant currency).

Brian Ward, AROA's CEO said: "*We are delighted with the strong performance reflected in these preliminary results, driven by continued growth in the Myriad portfolio. We look forward to providing further details on the release of our audited full year results at the end of May*".

Full Year FY26 Audited Results Release

The Company intends to release fully audited FY26 results on Tuesday 26 May 2026 and will host an investor webinar to discuss the results in full. Details of the investor webinar, including the link to register, will be provided in the coming weeks.

Authorised on behalf of the Aroa Biosurgery Limited Board of Directors by Brian Ward, CEO.

¹ Constant currency removes the impact of exchange rate movements and is used to assess AROA's underlying comparative financial performance. An exchange rate of US\$0.60/NZ\$1.00 has been used in the constant currency analysis for FY26.

² Normalised EBITDA is non-conforming financial information, as defined by the NZ Financial Markets Authority, and has been provided to assist users of financial information to better understand and assess the Group's comparative financial performance without distortion from one-off transactions. The impact of non-cash share-based payments expense and unrealised foreign exchange gains or losses has also been removed. This approach is used by Management and the Board to assess the Group's comparative financial performance.



Contacts

Investor Relations

investor@aroa.com

Eleonora De Vos +61 450 930 010

Media

sarah.tora@aroa.com

+64 21 531 043

About AROA™

Aroa Biosurgery is a soft-tissue regeneration company committed to 'unlocking regenerative healing for everybody'.

We develop, manufacture, sell and distribute medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Our products are developed from a proprietary AROA ECM™ technology platform, a novel extracellular matrix biomaterial derived from ovine (sheep) forestomach.

Over 7 million AROA products have been used globally in a range of procedures to date, with distribution into our key market of the United States via our direct sales force and our partner TELABio, Inc.

Founded in 2008, AROA is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX: ARX). www.aroa.com